Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Rhea-AI Summary

Pulmatrix (NASDAQ: PULM) announced Q2 2024 financial results and corporate updates. Key highlights include:

• $12.4 million in cash and cash equivalents, with an additional $1.4 million in restricted cash becoming unrestricted in August 2024
• Projected cash runway extended into Q4 2026
• Completed transactions with MannKind , validating iSPERSE™ technology
• Pursuing strategic alternatives for PUR3100 and iSPERSE™ technology
• Revenues decreased to $1.6 million in Q2 2024 from $1.8 million in Q2 2023
• R&D expenses decreased to $2.8 million from $4.2 million year-over-year
• Net loss of $5.8 million in Q2 2024 compared to $3.8 million in Q2 2023

The company is focusing on cost-saving measures and exploring partnerships for its clinical assets.

Positive

• Extended cash runway into Q4 2026, providing financial stability
• Completed transactions with MannKind , validating iSPERSE™ technology
• PUR3100 is Phase 2-ready with FDA acceptance of IND application
• Decreased R&D expenses by $1.3 million year-over-year

Negative

• Revenues decreased by $0.3 million compared to Q2 2023
• Net loss increased to $5.8 million from $3.8 million year-over-year
• Recognized a $2.6 million loss on disposal group of held for sale assets
• Stopped patient enrollment for PUR1900 Phase 2b study

Financial Analyst

Pulmatrix's Q2 2024 results reveal a mixed financial picture. While the company has extended its cash runway into Q4 2026, there are concerning trends:

• Revenue decreased by $0.3 million to $1.6 million, primarily due to winding down the PUR1900 Phase 2b trial.
• R&D expenses decreased by $1.3 million, reflecting reduced clinical activity.
• G&A expenses increased by $0.3 million, mainly due to higher legal costs.
• A $2.6 million loss was recognized on assets held for sale to MannKind

The $12.4 million cash position, plus $1.4 million in restricted cash, provides a runway into Q4 2026. However, the company's pivot to a virtual model and focus on strategic alternatives suggest challenges in advancing its pipeline independently.

Biotech Research Analyst

Pulmatrix's pipeline strategy is undergoing significant changes:

• PUR3100 (inhaled DHE for migraines) is Phase 2-ready, but requires external funding or partnerships to progress.
• PUR1800 (for AECOPD) showed promising Phase 1b results but needs partnerships to advance.
• PUR1900 Phase 2b study has been halted, with wind-down expected in Q3 2024.

The company's focus on its iSPERSE™ technology and PUR3100 indicates a narrowing of priorities. While the technology has potential, the need for external support across all programs suggests internal resources for clinical development. The transition to a virtual company model further underscores the challenges in advancing multiple programs simultaneously.

Market Strategist

Pulmatrix's strategic pivot presents a high-risk, high-reward scenario for investors. The company is betting heavily on its iSPERSE™ technology and the potential of PUR3100, while scaling back other operations. This approach could streamline costs but also increases dependency on external partnerships.

The extended cash runway provides a buffer for strategic maneuvering, but the company's ability to secure partnerships or funding for its key programs will be crucial. The 2% royalty agreement with Cipla for PUR1900 outside the U.S. offers some potential future revenue, albeit

Investors should closely monitor Pulmatrix's progress in securing partnerships, particularly for PUR3100, as this will be a key indicator of the company's future prospects and the market's validation of its technology platform.

Completed series of transactions with MannKind Corporation validating iSPERSE™ technology and extending projected cash runway into Q4 2026

$12.4 million in cash and cash equivalents at the end of Q2 2024, with an additional $1.4 million in restricted cash becoming unrestricted in August 2024

Pursuing strategic alternatives to further leverage iSPERSE™ and optimize the potential of PUR3100

FRAMINGHAM, Mass., Aug. 13, 2024 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary disease using its patented dry powder inhalation iSPERSE™ technology, today announced second quarter financial results for 2024 and provided a corporate update on its clinical assets.

Peter Ludlum, Interim Chief Executive Officer of Pulmatrix, commented, "Our focus in the second quarter has been to continue our cost saving measures, to complete the transactions with MannKind and to continue the wind down of the Phase 2b study for PUR1900. We believe that this has allowed us to reposition ourselves as a virtual company while continuing to focus on strategic alternatives that leverage the potential of PUR3100 and our iSPERSE™ technology."

Second Quarter 2024 and Recent Program and Corporate Highlights

PUR3100

• PUR3100 is an orally inhaled dihydroergotamine (DHE) engineered with iSPERSE™ for the treatment of acute migraine. Pulmatrix is currently exploring financing or partnership arrangements to develop and initiate a potential Phase 2 clinical study for PUR3100.
• In 2023, Pulmatrix announced the FDA's acceptance of an IND application for PUR3100 and receipt of a "study may proceed" letter to proceed with a Phase 2 study, positioning PUR3100 as Phase 2-ready. The IND includes a Phase 2 clinical protocol where safety and preliminary efficacy of PUR3100 will be investigated in patients with acute migraine.
• The planned Phase 2 trial builds on the Phase 1 trial results, which were published in 2023 and presented at the American Headache Society's 65^th Annual Meeting in June 2023. In May 2024, Pulmatrix announced a peer-reviewed publication of Phase 1 clinical results in the publication Headache: The Journal of Head and Face Pain.
• The study showed that PUR3100 achieved peak exposures in the targeted therapeutic range and time to maximum concentration occurred at five minutes after dosing at all dosing levels. The PUR3100 dose groups also showed a lower incidence of nausea and no vomiting compared to observations of nausea and vomiting in the intravenously (IV) administered DHE dose group.

PUR1800

• PUR1800 is a Narrow Spectrum Kinase Inhibitor, engineered with our iSPERSE™ technology, for the treatment of acute exacerbations in chronic obstructive pulmonary disease (AECOPD). In 2023, Pulmatrix presented complete results from a Phase 1b study of PUR1800 for AECOPD, indicating PUR1800 was safe and well tolerated with no observed safety signals. The topline data, along with the results from chronic toxicology studies, support the continued development of PUR1800 for the treatment of AECOPD and other inflammatory respiratory diseases.
• Pulmatrix plans to pursue partnership or other alternatives to monetize or advance PUR1800.

PUR1900

• PUR1900 is the Company's inhaled iSPERSE™ formulation of the antifungal drug itraconazole for indications where an orally inhaled antifungal may provide a therapeutic benefit or fulfill an unmet medical need. In agreement with its partner Cipla, Pulmatrix has stopped patient enrollment for the Phase 2b study of PUR1900. The decision to stop the study was unrelated to any safety concerns. This study had been ongoing since the first quarter of 2023. The Company remains on track to complete all Phase 2b wind down activities within the third quarter of 2024.
• After the study wind down, Pulmatrix will bear no further financial responsibility for the development of PUR1900 and will receive 2% royalties on any potential future net sales by Cipla outside the United States. Within the United States, Pulmatrix and Cipla will seek to monetize PUR1900.

Second Quarter 2024 Financial Results

Revenues decreased approximately $0.3 million to $1.6 million for the three months ended June 30, 2024, compared to $1.8 million for the three months ended June 30, 2023. The decrease is primarily related to the continued winding down of the PUR1900 Phase 2b clinical trial, for which the Company incurred fewer expenses eligible for reimbursement under its Agreement with Cipla as compared to the corresponding period in the previous year.

Research and development expenses decreased approximately $1.3 million to $2.8 million for the three months ended June 30, 2024, compared to $4.2 million for the three months ended June 30, 2023. The decrease was primarily due to winding down the PUR1900 Phase 2b clinical trial.

General and administrative expenses increased approximately $0.3 million to $2.0 million for the three months ended June 30, 2024, compared to $1.7 million for the three months ended June 30, 2023. The increase was primarily due to an increase in incurred legal costs.

The company recognized a $2.6 million loss on its disposal group of held for sale assets as of June 30, 2024, representing the current period write-down for the fair value of certain assets to be transferred to MannKind Corporation in the third quarter of 2024.

The Company's total cash and cash equivalents balance as of June 30, 2024, was $12.4 million plus $1.4 million in short-term restricted cash, which was released in August 2024, providing additional cash available to use in operations. The Company anticipates that its cash position, based on operational efficiencies and prioritization of spending, is sufficient to fund its operations into the fourth quarter of 2026.

PULMATRIX, INC.
Consolidated Balance Sheets
(in thousands, except share and per share data)
		June 30, 2024				December 31, 2023
		(unaudited)
Assets
Current assets:
Cash and cash equivalents		$	12,379			$	19,173
Restricted cash			1,421				-
Accounts receivable			635				928
Prepaid expenses and other current assets			1,201				742
Total current assets			15,636				20,843
Property and equipment, net			-				1,158
Operating lease right-of-use asset			-				10,309
Long-term restricted cash			51				1,472
Other long-term assets			93				176
Total assets		$	15,780			$	33,958
Liabilities and stockholders' equity
Current liabilities:
Accounts payable		$	393			$	1,915
Accrued expenses and other current liabilities			1,783				947
Operating lease liability			24				429
Deferred revenue			270				618
Total current liabilities			2,470				3,909
Deferred revenue, net of current portion			-				3,727
Operating lease liability, net of current portion			-				8,327
Total liabilities			2,470				15,963
Stockholders' equity:
Preferred stock, $0.0001 par value — 500,000 shares authorized; 6,746 shares designated Series A convertible preferred stock; no shares issued and outstanding at June 30, 2024 and December 31, 2023			-				-
Common stock, $0.0001 par value — 200,000,000 shares authorized; 3,652,285 shares issued and outstanding at June 30, 2024 and December 31, 2023			-				-
Additional paid-in capital			305,893				305,592
Accumulated deficit			(292,583)				(287,597)
Total stockholders' equity			13,310				17,995
Total liabilities and stockholders' equity		$	15,780			$	33,958

 

PULMATRIX, INC.
Consolidated Statements of Operations
(in thousands, except share and per share data)
(unaudited)
		Three Months Ended June 30,								Six Months Ended June 30,
		2024				2023				2024				2023
Revenues		$	1,552			$	1,844			$	7,437			$	3,343
Operating expenses:
Research and development			2,834				4,165				6,346				8,039
General and administrative			2,001				1,670				3,627				3,880
Loss on disposal group held for sale			2,618				-				2,618				-
Total operating expenses			7,453				5,835				12,591				11,919
Loss from operations			(5,901)				(3,991)				(5,154)				(8,576)
Other income (expense):
Interest income			133				236				293				458
Other expense, net			(43)				(61)				(125)				(146)
Total other income (expense), net			90				175				168				312
Net loss		$	(5,811)			$	(3,816)			$	(4,986)			$	(8,264)
Net loss per share attributable to common stockholders – basic and diluted		$	(1.59)			$	(1.04)			$	(1.37)			$	(2.26)
Weighted average common shares outstanding – basic and diluted			3,652,285				3,652,285				3,652,285				3,651,531

About Pulmatrix, Inc.
Pulmatrix is a clinical-stage biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat central nervous system ("CNS"), respiratory and other diseases with important unmet medical needs using its patented iSPERSE™ technology. The Company's proprietary product pipeline includes treatments for CNS disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease ("COPD") and allergic bronchopulmonary aspergillosis ("ABPA"). Pulmatrix's product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE™, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.

For more on the Company's inhaled product candidates please visit:
https://www.pulmatrix.com/pipeline.html.

Forward-Looking Statements
Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements include, but are not limited to, statements of historical fact and may be identified by words such as "anticipates," "assumes," "believes," "can," "could," "estimates," "expects," "forecasts," "guides," "intends," "is confident that", "may," "plans," "seeks," "projects," "targets," and "would," and their opposites and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the Company's ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; the ability to secure and enforce legal rights related to the Company's products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact:
Timothy McCarthy, CFA
917-679-9282
tim@lifesciadvisors.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/pulmatrix-announces-second-quarter-2024-financial-results-and-provides-corporate-update-302220668.html

SOURCE Pulmatrix Inc.

FAQ

What was Pulmatrix's (PULM) cash position at the end of Q2 2024?

Pulmatrix had $12.4 million in cash and cash equivalents at the end of Q2 2024, with an additional $1.4 million in restricted cash becoming unrestricted in August 2024.

How did Pulmatrix's (PULM) revenue change in Q2 2024 compared to Q2 2023?

Pulmatrix's revenues decreased by approximately $0.3 million to $1.6 million in Q2 2024, compared to $1.8 million in Q2 2023.

What is the current status of Pulmatrix's (PULM) PUR3100 program?

PUR3100 is Phase 2-ready with FDA acceptance of an IND application. Pulmatrix is exploring financing or partnership arrangements to initiate a potential Phase 2 clinical study.

How long does Pulmatrix (PULM) expect its current cash position to last?

Pulmatrix anticipates that its current cash position is sufficient to fund operations into the fourth quarter of 2026.